UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1075-14
Program Prior Authorization/Notification
Medication *Orencia® (abatacept)
*This program applies to the subcutaneous formulation of abatacept
P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,
11/2011, 7/2012, 11/2012, 2/2014, 2/2015, 3/2016, 3/2017, 8/2017, 8/2018,
8/2019, 8/2020, 8/2021, 8/2022, 7/2023, 1/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Orencia (abatacept) is a selective T-cell costimulation modulator indicated for the treatment
of adult patients with moderately to severely active rheumatoid arthritis (RA), patients 2
years of age and older with moderately to severely active polyarticular juvenile idiopathic
arthritis (JIA), and patients 2 years of age and older with active psoriatic arthritis (PsA).
Concomitant use of Orencia with other immunosuppressives [e.g., biologic disease-
modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not
recommended.
2. Coverage Criteriaa:
A. Rheumatoid Arthritis (RA)
1. Initial Authorization
a. Orencia will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active rheumatoid arthritis
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),
Olumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Orencia will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Orencia therapy
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),
Olumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
B. Juvenile Idiopathic Arthritis (JIA)
1. Initial Authorization
a. Orencia will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic
arthritis.
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),
Olumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Orencia will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Orencia therapy
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),
Olumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
C. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Orencia will be approved based on both of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
© 2025 UnitedHealthcare Services, Inc.
2
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx
(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Otezla (apremilast),
Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara
(ustekinumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Orencia will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Orencia therapy
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx
(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Otezla (apremilast),
Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara
(ustekinumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Supply limits, Medical Necessity and/or Step Therapy may be in place.
• The intravenous infusion is typically covered under the medical benefit. Please refer to the
United Healthcare Medical Benefit Drug Policy for Orencia.
4. References:
1. Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; May 2024.
Program Prior Authorization/Notification - Orencia (abatacept)
Change Control
2/2014 Background updated. Concomitant therapy criterion condensed to list
four biologic DMARDs and revised to include Xeljanz. Reauthorization
criteria revised to standard verbiage and to include concomitant therapy
criterion. Extended reauthorization duration to 24 months.
2/2015 Annual review with no change to coverage criteria. Minor reformatting.
Updated clinical rules and background.
3/2016 Annual review with no change to the coverage criteria. Updated
statement regarding scope of the program. Added reference to UHC
drug policy for intravenous infusions. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3
3/2017 Annual review with no change to coverage criteria. Updated
background and references.
8/2017 Added psoriatic arthritis to coverage criteria. Updated background and
references.
8/2018 Annual review. Added Olumiant (baricitinib) to applicable criteria.
Updated background.
8/2019 Annual review with no change to coverage criteria. Updated
background and references.
8/2020 Annual review. Updated reauthorization duration to 12 months.
Updated background and references.
8/2021 Annual review with no changes to coverage criteria.
8/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote. Updated background and reference.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
1/2024 Updated Background for updated indication for PsA for patients 2 years
of age and older. Updated reference.
1/2025 Annual review. Updated examples with no change to clinical intent.
Updated reference.
© 2025 UnitedHealthcare Services, Inc.
4